ClinicalTrials.gg
CompletedNCT01745588Updated Sep 25, 2026Results posted

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

A Phase 2 interventional study of Pomalidomide and stem cell in Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
269th of 373
23 · median 45
Started
2012
with 13 others
Phase 2
217 of 381
18 open now
Registered
144th of 381
by date
Lead sponsor
12 of 381
Memorial Sloan Kettering Cancer Center

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 269th largest by enrollment of the 373 interventional ones that give a count, is one of 14 that started in 2012, is one of 217 in phase 2, and was the 144th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to see whether pomalidomide (also known as Pomalyst) reduces the number of myeloma cells in the bones, and to see what is the best way to use pomalidomide in patients with myeloma. To do this, the investigators want to compare two types of treatment using pomalidomde. This is a randomized trial which means that the decision as to which treatment the patient will receive will be made by a computer, much like flipping a coin.

All patients start by receiving 4 cycles of clarithromycin, pomalidomide and dexamethasone (ClaPD). After 4 cycles, half of the patients will undergo an autologous stem cell transplant followed by pomalidomide (Group 1). The other half of the patients will continue to receive ClaPD for 9 cycles to be followed by pomalidomide maintenance. (Group 2).

At the end of the study, the two groups will be compared to see if there is a difference in disease outcome.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • CC-4047(Pomalidomide)Pomalyst
  • Clarithromycin
  • Biaxin
  • DEXAMETHASONE
  • (ClaPD)
  • Stem cell
  • 12-138
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed multiple myeloma as defined by the International Myeloma Working Group (IMWG).
  • Patients must have as defined by the International Uniform Response Criteria, defined as any of the following:
  • serum M-protein of ≥ 500mg/dL
  • urine M-protein of ≥ 200mg/ 24 hours
  • involved free light chain ≥ 10mg/dL provided serum free light chain ratio is abnormal
  • Patients must have had a previous auto-SCT performed as part of a consolidation of an initial remission and had a remission, defined as a partial response or greater that lasted at least 12 months either on or off maintenance therapy without evidence of progression as defined by IMWG criteria.
  • Patients who are post auto-SCT as primary therapy must have received maintenance therapy with lenalidomide.
  • Patients must be registered within 6 months of last dose of lenalidomide.
  • Minimum of 3 months of maintenance therapy prior to disease progression.
  • Age ≥ 18 years.
  • of ≥12 weeks.
  • ≥ 70 or \< 1 (Appendix IV)
  • Patients must have adequate organ and marrow function as defined below:
  • ≥ 750/μL
  • ≥ 50,000/μL
  • Total ≤ 1.5 mg/dL
  • (SGOT) ≤ 3 X .
  • ALT(SGPT) ≤ 3 X upper limit of normal.
  • Cardiac ≥ 40%
  • Serum Creatinine ≤ 2.0 mg/dL
  • Patients must have an adequate number of CD34+ stem cells collected to allow for transplantation (defined as ≥ 2x10\^6 CD34+ cells / kg body weight). If not previously collected and stored or if previous collection was inadequate, the patient must be willing to undergo stem cell mobilization and collection as per standard practice.
  • Patients who participate in this study must be willing and able to tolerate prophylactic anticoagulation either with aspirin, low-molecular weight heparin (LMWH), or warfarin.
  • Ability to understand and the willingness to sign a written document.
  • Patient must be determined fit to undergo auto-SCT procedure by a study physician.
  • Females of must adhere to the scheduled pregnancy testing as required in the POMALYST REMS™ program. Females of (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing pomalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of , one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.

    • A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 24 consecutive months (i.e.,has had menses at any time in the preceding 24 consecutive months).
  • All study participants must be registered into the mandatory POMALYST REMS™ program, and be willing and able to comply with the requirements of the POMALYST REMS™ program.

    • A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Exclusion criteria

Exclusion Criteria:

  • Patients who have had myeloma therapy within 14 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Patients may have received bisphosphonate therapy or radiation therapy as part of routine myeloma care at any time prior to study entry.
  • Patients may not be receiving any other agents.
  • Any prior use of thalidomide or pomalidomide.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (including thalidomide) clarithromycin, or melphalan.
  • Known prior positivity for active or infectious hepatitis, type B or C.
  • Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure , unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.
  • History of thrombosis or thromboembolic event within last 30 days prior to study entry.
  • Patients with CNS involvement.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Clarithromycin + Pomalidomide + Dexamethasone + stem cell

    All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.

    Drug: Pomalidomide · Procedure: stem cell · Drug: Clarithromycin

  • Experimental
    Clarithromycin + Pomalidomide + Dexamethasone Alone

    All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.

    Drug: Pomalidomide · Drug: Dexamethasone · Drug: Clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Very Good PR or greater will be evaluated nine months postrandomization according to International Uniform Response Criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: at 9 months after the start of treatment

Secondary outcomes

  1. Number of Participants With Adverse Events

    The frequency of subjects experiencing a specific adverse event will be tabulated overall and by each treatment course. In the by-subject analysis, a subject having the same event more than once will be counted only once. Adverse events will be summarized by worst NCI CTCAE grade. Laboratory data will be graded according to NCI CTCAE severity grade

    Time frame: 3 years

  2. Overall Survival

    Time frame: up to 94 months

  3. Progression Free Survival

    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: up to 94 months

  4. Median Overall Survival

    Overall survival rate

    Time frame: up to 118 months

07

Results

Posted Sep 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Started1211
Completed32
Not completed99
Withdrew: Death88
Withdrew: Lost to follow-up11

Outcome measures

PrimaryOverall Response Rate

Very Good PR or greater will be evaluated nine months postrandomization according to International Uniform Response Criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
at 9 months after the start of treatment
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Overall Response Rate (Partial Response or Better)85
Stable Disease or Progression46
SecondaryNumber of Participants With Adverse Events

The frequency of subjects experiencing a specific adverse event will be tabulated overall and by each treatment course. In the by-subject analysis, a subject having the same event more than once will be counted only once. Adverse events will be summarized by worst NCI CTCAE grade. Laboratory data will be graded according to NCI CTCAE severity grade

Time frame:
3 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Number of Participants With Adverse Events1211
SecondaryOverall Survival
Time frame:
up to 94 months
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Death from Disease88
Alive43
SecondaryProgression Free Survival

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
up to 94 months
Reported as:
Median · months
Progression Free Survival
monthsClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Progression Free Survival16 (2 to 94)9 (3 to 88)
SecondaryMedian Overall Survival

Overall survival rate

Time frame:
up to 118 months
Reported as:
Median · months
Median Overall Survival
monthsClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Median Overall Survival35 (10 to 118)47 (3 to 88)

Adverse events

Collected over up to 118 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell8/12 (66.7%)5/12 (41.7%)8/12 (66.7%)
Clarithromycin + Pomalidomide + Dexamethasone Alone8/11 (72.7%)5/11 (45.5%)6/11 (54.5%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Lung infectionInfections and infestations3/121/11
Cardiac arrestCardiac disorders0/121/11
FatigueGeneral disorders0/121/11
HyperglycemiaMetabolism and nutrition disorders1/121/11
HyperkalemiaMetabolism and nutrition disorders0/121/11
ConfusionPsychiatric disorders0/121/11
DyspneaRespiratory, thoracic and mediastinal disorders0/121/11
Resp, thoracic & mediastinal disorder Other, specRespiratory, thoracic and mediastinal disorders1/121/11
Thromboembolic eventVascular disorders0/121/11
HypercalcemiaMetabolism and nutrition disorders0/121/11
Most frequent other events
Showing 10 of 119
Most frequent other events
EventClarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone Alone
Creatinine increasedInvestigations0/125/11
HyperglycemiaMetabolism and nutrition disorders2/125/11
AnemiaBlood and lymphatic system disorders2/124/11
Edema limbsGeneral disorders1/124/11
HyperkalemiaMetabolism and nutrition disorders0/124/11
Neutrophil count decreasedInvestigations3/124/11
TremorNervous system disorders0/124/11
White blood cell decreasedInvestigations2/124/11
BUN increaseInvestigations0/123/11
DyspneaRespiratory, thoracic and mediastinal disorders3/123/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Clarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone AloneTotal
Mean59.5 (47 to 74)61 (45 to 67)60.2 (45 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Clarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone AloneTotal
Female6713
Male6410
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Clarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone AloneTotal
Hispanic or Latino202
Not Hispanic or Latino10919
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Clarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone AloneTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander011
Black or African American628
White5712
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)Clarithromycin + Pomalidomide + Dexamethasone + Stem CellClarithromycin + Pomalidomide + Dexamethasone AloneTotal
United States121123
08

Study locations

10 sites
  • Memorial Sloan Kettering Cancer Center
    Basking Ridge, New Jersey, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk
    Commack, New York 11725, United States
  • Memorial Sloan Kettering West Harrison
    Harrison, New York 10604, United States
  • North Shore LIJ
    New Hyde Park, New York 11040, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Medical College of Cornell University
    New York, New York, United States
  • Memorial Sloan Kettering Cancer Center at Mercy Medical Center
    Rockville Centre, New York 11570, United States
  • Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center
    Sleepy Hollow, New York 10591, United States
  • SUNY Upstate Medical University
    Syracuse, New York, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Sep 2025 and a completion of Sep 2025. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2012
First posted
Dec 10, 2012
Start
Dec 2012
Primary completionActual
Sep 3, 2025
CompletionActual
Sep 3, 2025
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Editedoverall response rateOverall Response RateTime frame: at 9 months after the start of treatment
Sep 25, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • Editedoverall survivalOverall SurvivalTime frame: 1 year → up to 94 months
  • Editedprogression free survivalProgression Free SurvivalTime frame: 1 year → up to 94 months
  • ChangedBefore safety analysesNow Number of Participants With Adverse EventsTime frame: 3 years
  • ChangedBefore Determine the rates of ≥ Grade 3 toxicitiesNow Median Overall SurvivalTime frame: 1 year → up to 118 months
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • Editedoverall response rateOverall Response RateTime frame: at 9 months after the start of treatment
    Secondary outcomes 4 edited
    What changed in the outcomes
    • Editedoverall survivalOverall SurvivalTime frame: 1 year → up to 94 months
    • Editedprogression free survivalProgression Free SurvivalTime frame: 1 year → up to 94 months
    • ChangedBefore safety analysesNow Number of Participants With Adverse EventsTime frame: 3 years
    • ChangedBefore Determine the rates of ≥ Grade 3 toxicitiesNow Median Overall SurvivalTime frame: 1 year → up to 118 months

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01745588
Collaborators
Celgene Corporation, Weill Medical College of Cornell University, North Shore University Hospital, Rutgers Cancer Institute of New Jersey, State University of New York - Upstate Medical University
Responsible party
Sponsor
First posted
Dec 10, 2012
Start date
Dec 2012
Primary completion
Sep 3, 2025
Completion
Sep 3, 2025
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Sergio Giralt, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion